Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laure Peyro Saint Paul

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Open Forum Infectious Diseases|April 6, 2019
Risk and Cost Associated With Drug-Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in FranceLudivine Demessine, Laure Peyro-Saint-Paul, Edward M Gardner, et al.
Expert Opinion on Drug Metabolism & Toxicology|December 25, 2015
Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosisLaure Peyro Saint Paul, Danièle Debruyne, Delphine Bernard, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|July 7, 2021
Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database AnalysisCharles Dolladille, Basile Chrétien, Laure Peyro-Saint-Paul, et al.
Therapie|June 14, 2014
[New frequent adverse reaction of PPI in older adults: mild hyponatremia]Laure Peyro Saint Paul, Jocelyne Martin, Marie Buon, et al.
Therapie|July 10, 2016
[Not Available]Laure Peyro Saint Paul, Jocelyne Martin, Marie Buon, et al.
Therapie|November 20, 2013
[Moderate potentially drug-induced hyponatremia in older adults: benefit in drug reduction]Laure Peyro Saint Paul, Jocelyne Martin, Cathy Gaillard, et al.
Trials|March 11, 2018
Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trialGilles Defer, Florian Le Caignec, Sophie Fedrizzi, et al.
Drug Safety|October 13, 2020
Adverse Drug Reaction Reporting Using a Mobile Device Application by Persons with Multiple Sclerosis: A Cluster Randomized Controlled TrialGilles Defer, Sophie Fedrizzi, Damien Chevanne, et al.
Trials|June 9, 2017
Real versus sham proximal biofield therapy in the treatment of warts of the hands and feet in adults: study protocol for a randomized controlled trial (MAGNETIK study)Cathy Gaillard, Laure Allain, Hélène Legros, et al.
Therapie|July 10, 2016
[Not Available]Laure Peyro Saint-Paul, Jocelyne Martin, Cathy Gaillard, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Open Forum Infectious Diseases|April 6, 2019
Risk and Cost Associated With Drug-Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in FranceLudivine Demessine, Laure Peyro-Saint-Paul, Edward M Gardner, et al.
Expert Opinion on Drug Metabolism & Toxicology|December 25, 2015
Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosisLaure Peyro Saint Paul, Danièle Debruyne, Delphine Bernard, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|July 7, 2021
Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database AnalysisCharles Dolladille, Basile Chrétien, Laure Peyro-Saint-Paul, et al.
Therapie|June 14, 2014
[New frequent adverse reaction of PPI in older adults: mild hyponatremia]Laure Peyro Saint Paul, Jocelyne Martin, Marie Buon, et al.
Therapie|July 10, 2016
[Not Available]Laure Peyro Saint Paul, Jocelyne Martin, Marie Buon, et al.
Therapie|November 20, 2013
[Moderate potentially drug-induced hyponatremia in older adults: benefit in drug reduction]Laure Peyro Saint Paul, Jocelyne Martin, Cathy Gaillard, et al.
Trials|March 11, 2018
Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trialGilles Defer, Florian Le Caignec, Sophie Fedrizzi, et al.
Drug Safety|October 13, 2020
Adverse Drug Reaction Reporting Using a Mobile Device Application by Persons with Multiple Sclerosis: A Cluster Randomized Controlled TrialGilles Defer, Sophie Fedrizzi, Damien Chevanne, et al.
Trials|June 9, 2017
Real versus sham proximal biofield therapy in the treatment of warts of the hands and feet in adults: study protocol for a randomized controlled trial (MAGNETIK study)Cathy Gaillard, Laure Allain, Hélène Legros, et al.
Therapie|July 10, 2016
[Not Available]Laure Peyro Saint-Paul, Jocelyne Martin, Cathy Gaillard, et al.
Pageof 3